Ultimovacs Dirección

Dirección controles de criterios 3/4

El CEO de Ultimovacs' es Carlos de Sousa , nombrado en Jun 2020, tiene una permanencia de 3.83 años. compensación anual total es NOK6.50M, compuesta por 74.5% salario y 25.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.076% de las acciones de la empresa, por valor de NOK205.84K. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 7.3 años, respectivamente.

Información clave

Carlos de Sousa

Chief Executive Officer (CEO)

kr6.5m

Compensación total

Porcentaje del salario del CEO	74.5%
Permanencia del CEO	3.9yrs
Participación del CEO	0.08%
Permanencia media de la dirección	4.6yrs
Promedio de permanencia en la Junta Directiva	7.3yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Jul 27

We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely

Mar 23

Have Insiders Sold Ultimovacs ASA (OB:ULTI) Shares Recently?

Feb 13

Insider Buying: The Ultimovacs ASA (OB:ULTI) Chief Executive Officer Just Bought 12% More Shares

Jan 14

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Carlos de Sousa en comparación con los beneficios de Ultimovacs?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	kr7m	kr5m	-kr189m
Sep 30 2023	n/a	n/a	-kr204m
Jun 30 2023	n/a	n/a	-kr186m
Mar 31 2023	n/a	n/a	-kr165m
Dec 31 2022	kr8m	kr5m	-kr168m
Sep 30 2022	n/a	n/a	-kr148m
Jun 30 2022	n/a	n/a	-kr153m
Mar 31 2022	n/a	n/a	-kr168m
Dec 31 2021	n/a	n/a	-kr165m
Sep 30 2021	n/a	n/a	-kr138m
Jun 30 2021	n/a	n/a	-kr126m
Mar 31 2021	n/a	n/a	-kr124m
Dec 31 2020	kr5m	kr3m	-kr121m

Compensación vs. Mercado: La compensación total de Carlos($USD590.49K) está por encima de la media de empresas de tamaño similar en el mercado Norwegian ($USD302.44K).

Compensación vs. Ingresos: La compensación de Carlos ha sido consistente con los resultados de la empresa en el último año.

CEO

Carlos de Sousa (65 yo)

3.9yrs

Permanencia

kr6,504,000

Compensación

Dr. Carlos de Sousa serves as Chief Executive Officer at Ultimovacs ASA since June 01, 2020. Dr. de Sousa served as Chief Executive Officer of Immunicum AB (publ) since October 1, 2016 until December 13, 2...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Carlos de Sousa	Chief Executive Officer	3.9yrs	kr6.50m	0.076% NOK 181.9k
Hans Eid	Chief Financial Officer	8.5yrs	kr4.41m	sin datos
Ingunn Westgaard	Head of Research	no data	kr2.57m	sin datos
Audun Tornes	Chief Technology Officer	3.3yrs	kr2.92m	sin datos
Anne Worsoe	Head of Investor Relations & ESG	2.6yrs	kr2.31m	sin datos
Jens Egil Bjorheim	Chief Medical Officer	7.9yrs	kr4.29m	sin datos
Oivind Foss	Head of Clinical Operations	6.8yrs	kr2.71m	sin datos
Gudrun Troite	Head of Project Coordination	6.8yrs	kr2.50m	sin datos
Antonius Berkien	Chief Business Officer	3.4yrs	kr4.43m	sin datos
Orla Mc Callion	Head of Regulatory Affairs & QA	2.6yrs	kr2.37m	sin datos
Gustav Gaudernack	Chief Scientific Officer	no data	sin datos	sin datos
Sara Mangsbo	Chief Innovation Officer	5.3yrs	sin datos	sin datos

4.6yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de ULTI se considera experimentado (4.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ketil Fjerdingen	Deputy Board member	no data	kr250.00k	sin datos
Jonas Einarsson	Independent Chairman	13.3yrs	kr450.00k	0.015% NOK 37.0k
Leiv Askvig	Independent Director	9.3yrs	kr320.00k	0.27% NOK 638.7k
Eva Dugstad	Independent Director	5.3yrs	kr250.00k	0.019% NOK 44.7k
Kari Gronas	Independent Director	5.3yrs	kr250.00k	0.019% NOK 46.3k
Henrik Schussler	Director	9.3yrs	kr250.00k	sin datos
Haakon Stenrod	Independent Director	3.5yrs	kr290.00k	sin datos

7.3yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de ULTI se considera experimentada (7.3 años de antigüedad promedio).

Ultimovacs Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Chief Executive Officer recently bought kr57k worth of stock

Ultimovacs ASA, Annual General Meeting, Apr 18, 2024

Chief Executive Officer recently bought kr145k worth of stock

Recent updates

Ultimovacs ASA Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program

Price target decreased by 8.6% to kr155

New minor risk - Market cap size

Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma

New minor risk - Share price stability

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma

Ultimovacs ASA Updates Timeline for Reporting on Randomized UV1 Phase II Trial Initium in Malignant Melanoma

Ultimovacs ASA to Report Q4, 2024 Results on Feb 13, 2025

Insufficient new directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors

Chief Executive Officer recently bought kr57k worth of stock

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Enrollment in Supplementary Study to INITium, UV1 Phase II Trial in Malignant Melanoma

Ultimovacs ASA Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024

Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Ultimovacs ASA Announces Full Dataset from the NIPU Clinical Trial (Nct04300244) Presented At the ESMO Congress 2023 in Madrid

Ultimovacs ASA Announces the Results from the NIPU clinical trial (NCT04300244)

New minor risk - Share price stability

Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with Uv1 Cancer Vaccine

Ultimovacs ASA Receives FDA Orphan Drug Designation for the Uv1 Cancer Vaccine for Treatment of Mesothelioma

Ultimovacs ASA Announces the Results from Uv1 Phase Ii Clinical Trial Nipu in Malignant Mesothelioma Will Be Presented At the Esmo Congress 2023

Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients

Ultimovacs ASA Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results

Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine

New minor risk - Share price stability

Ultimovacs ASA Provides Update on Phase II NIPU Trial Evaluating UV1 in Second-Line Patients with Malignant Leural Mesothelioma

No longer forecast to breakeven

Ultimovacs ASA Announces Completion of Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma

Ultimovacs ASA, Annual General Meeting, Apr 18, 2024

Ultimovacs ASA Announces Cemiplimab to Replace Pembrolizumab in V1 Phase II LUNGVAC Trial

Ultimovacs ASA Completes Last Patient Enrollment in Phase I TENDU Trial in Prostate Cancer

Chief Executive Officer recently bought kr145k worth of stock

Forecast to breakeven in 2023

No independent directors

No longer forecast to breakeven

Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs Asa Announces New Uv1 Data Showing Enhanced Efficacy Including in Hard-To-Treat Cancer Patients, Supporting Broad Utility

Ultimovacs ASA Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma

Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Ultimovacs ASA Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine

Chief Executive Officer recently bought kr134k worth of stock

Price target increased to kr151

Ultimovacs ASA Expands High Dose Cohort Size in Tendu Phase I Prostate Cancer Trial After Safety Review

Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

Ultimovacs ASA Announces UV1 Cancer Vaccine Shows Strong Overall Survival in Malignant Melanoma Phase I Trial

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

Ultimovacs Announces Presentation of UV1 Immune Monitoring Data At Cancer Immunotherapy Annual Meeting

Price target increased to kr151

No independent directors

Ultimovacs ASA Approves Board and Committee Changes

Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development

Chief Executive Officer recently bought kr94k worth of stock

Ultimovacs ASA Completes Treatment of the Second Dose Cohort in the Phase I TENDU Trial

Ultimovacs ASA Announces First Patient Enrolled in Phase II DOVACC Trial of UV1 in Advanced Ovarian Cancer

Chief Executive Officer recently bought kr228k worth of stock

Ultimovacs Asa Announces Further Positive Topline Results from Phase I Uv1 Cancer Vaccine Combination Study in Metastatic Melanoma

Ultimovacs Announces First Patient Enrolled in Phase II Focus Trial of UV1 in Head-And-Neck Cancer

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Ultimovacs’ Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines

Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program

Ultimovacs ASA Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma

Deputy Board Member recently bought kr388k worth of stock

Chief Executive Officer recently bought kr91k worth of stock

Forecast to breakeven in 2023

Ultimovacs ASA’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data

Price target increased to kr125